当前位置: 首页 > 期刊 > 《湖南中医学院学报》 > 20202
编号:13509539
中药治疗肝衰竭机制的研究进展(5)
http://www.100md.com 2020年2月1日 《湖南中医药大学学报》 20202
     [26] 石清兰,毛德文,陈月桥,等.解毒化瘀Ⅱ方对HBV相关急性肝衰竭患者外周血Th17、Th1表达及临床疗效的影响[J].中国医药导报,2018,15(21):122-125.

    [27] UCHIDA T, HIRAGA N, IMAMURA M, et al. Human cytotoxic T lymphocyte-mediated acute liver failure and rescue by Immunoglobulin in human hepatocyte transplant TK-NOG mice[J]. Journal of Virology, 2015, 89(19):10087.

    [28] WANG K. Molecular mechanisms of liver injury: Apoptosis or nec?rosis[J]. Experimental & Toxicologic Pathology Official Journal of the Gesellschaft Für Toxikologische Pathologie,2014,66(8):351-356.

    [29] 劉 茵,王明刚,毛德文,等.解毒化瘀颗粒对肝衰竭大鼠外周CTL、Treg细胞的影响研究[J].时珍国医国药,2018,29(6):1290-1293.

    [30] YANG H, TRACEY K J. Targeting HMGB1 in inflammation[J]. BBA-Gene Regulatory Mechanisms, 2010, 1799(1):149-156.

    [31] LU-WENWANG, CHEN H, GONG Z J. High mobility group box-1 protein inhibits regulatory T cell immune activity in liver failure in patients with chronic hepatitis B[J]. Hepatobiliary & Pancreatic Diseases International, 2010, 9(5):499-507.

    [32] 扈晓宇,张 扬.清热化瘀中药复方对急性肝衰竭大鼠肝组织HMGB1表达的干预研究[J].中国实验方剂学杂志,2013,19(2):172-177., 百拇医药(张荣臻 王挺帅 吕超 毛德文 孙克伟)
上一页1 2 3 4 5